Histone H3 G34 Mutations in Paediatric High-Grade Glioma

A Local Rather Than Global Effect

Glycine 34 lies next to lysine 36. A bulky substitution at G34 impairs the deposition and reading of H3K36 methylation on the same histone tail, altering transcription and splicing in a way that is more locally restricted than the genome-wide effect of K27M.

G34-mutant gliomas frequently carry additional alterations in TP53 and ATRX, and most maintain their telomeres through the alternative lengthening of telomeres mechanism.

Clinical and Molecular Distinctiveness

These tumours are hemispheric, occur at a slightly older age than K27M tumours, and form a distinct group by DNA-methylation profiling. They are now recognised as a separate tumour type, diffuse hemispheric glioma, H3 G34-mutant, in the WHO classification.

Outcomes are poor but on average somewhat less rapidly fatal than for diffuse midline glioma.

Repair and Immune Features

Laboratory models indicate that G34 mutation downregulates DNA-repair pathways, increasing sensitivity to DNA damage and to inhibitors of the damage response, and that resulting genomic instability can activate innate immune signalling through the cGAS-STING pathway.

These are preclinical observations that are being explored as combination strategies with radiotherapy, not current treatments.

Diagnosis and What It Changes

Diagnosis rests on detecting the G34R or G34V substitution by sequencing, supported by DNA-methylation profiling that places the tumour in its own class and by the frequent companion findings of TP53 and ATRX mutation. The distinction from other paediatric high-grade gliomas matters mainly for prognosis and trial allocation.

Because most G34 tumours use alternative lengthening of telomeres and show reduced DNA-repair capacity in models, they are candidates for trials combining radiotherapy with damage-response inhibitors, and MGMT promoter methylation is assessed as it would be in adult glioblastoma to inform alkylating-agent use.

Key Takeaways

• ·H3.3 G34R/V mutations disrupt nearby H3K36 methylation, a more local effect than K27M.
• ·G34-mutant gliomas are hemispheric, often TP53- and ATRX-altered, and typically use ALT.
• ·Preclinical work links G34 mutation to impaired DNA repair and cGAS-STING immune activation.